| Name | Title | Contact Details |
|---|
Fresno Surgical Hospital (FSH) is a fully-licensed, Joint Commission-accredited hospital that delivers award-winning surgical care and patient satisfaction. We are a physician-owned hospital that focuses solely on providing advanced, affordable surgical care. Each year, FSH serves approximately 12,000 patients in our Central California service area including: Fresno, Madera, Merced, Kings and Tulare Counties. Our patients enjoy a non-traditional, hotel-like setting and a commitment to quality care and patient satisfaction. Twenty-seven private inpatient suites give patients and their families an environment that promotes relaxation, comfort and healing. FSH was founded by two orthopedic surgeons, Alan H. Pierrot, MD and Thomas Thaxter, MD, who had a vision of improving healthcare. Originally named Fresno Surgery Center (FSC), the facility opened as an outpatient surgery center in 1984. Within the first year, FSC was in the top 10 percent of all freestanding outpatient surgery centers in the nation, based on the number of patients served. The center`s approach to patient service was also unique. The rare combination of compassion, hospitality and surgical excellence continues to be our distinguishing factor. We were the first facility in the United States to provide elective surgery and post-surgical care in a non-hospital setting. Overwhelming popularity among patients, surgeons and staff established FSC as the leader in the nationwide trend toward elective surgery facilities. In fact, we have consistently been recognized as a top performer both in the state of California and nationally.
Deep Hospitality Knowledge Mission Hill Hospitality is the KSL Capital portfolio company launched to transform select service and extended stay hotel investing. KSL is a global leader in hospitality, travel, and leisure investing. The Mission Hill team has decades of lodging experience, with a wide range of expertise across functions including operations, asset management, acquisitions, development, and capital markets. Industry Advantage Mission Hill`s approach combines the benefits of KSL`s world-leading, world-class hospitality model, with our seasoned team`s broad relationships with owners, managers, premium brands, and developers, enabling us to create the highest quality asset portfolio. Value Added Mission Hill`s value-add strategy seeks to maximize the performance of each investment while elevating the client experience. By hand-picking assets in preferred markets across the country, we avoid inherent information asymmetry and premiums associated with acquiring a portfolio. Our disciplined approach to underwriting gives us the ability to secure outsized risk adjusted returns.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.
Acadian Companies is a Lafayette, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Commonwealth Diagnostics International (CDI), Inc., was founded on the principle that preventative healthcare, including early detection and diagnosis of disease, results in expedited treatment, better patient outcomes, and robust cost savings for the healthcare delivery system. Operating out of a newly constructed laboratory in Salem, MA, CDI is an international diagnostic service provider specializing in innovative diagnostic products that assist physicians and patients with the diagnosis and management of some of the world`s most common sources of digestive distress and functional gastrointestinal disorders, including: hydrogen (H2)/methane (CH4) breath testing for Small Intestinal Bacterial Overgrowth (SIBO) and carbohydrate malabsorption, IBSchek™ for IBS-D/M; and AbStats™, an easy-to-use, noninvasive, and reliable digestive telemetry and sensory system. CDI focuses on creating customized operational solutions to diagnostic technologies that drive accessibility and simplicity in lieu of outdated, expensive, invasive, and inaccessible diagnostic modalities. CDI`s entire portfolio of tests can be utilized either at home or with one simple trip to the physician. CDI`s laboratory specializes in customized gas chromatography, ELISA, and isotope-ratio mass spectrometry solutions.